Immodulon, the immuno-oncology company, today announces the appointment of Dr Jaap Kampinga, current Chief Scientific Officer (CSO), as Chief Executive Officer (CEO) effective from 1st July 2018. Dr Kampinga is a medical doctor and immunologist and has considerable experience from previous academic and management roles in the life science sector. Dr Kampinga joined as CSO in January 2018. Until May Jaap was Chairman of the Dutch drug development company, Xenikos BV, stepping down following the company’s successful US$30 million fund raise. Jaap’s career to date has included academic, senior R&D, CEO and Chairman roles in various medical companies, and he has been CEO of two other drug development companies with drug compounds derived from bacteria. He has also served as a senior partner at a London-based investment boutique firm involved in starting, building and organizing finance for early stage medical companies. Kevin Bilyard, Immodulon’s current interim CEO, will continue to work alongside Dr Jaap until 1 October 2018 and will join the Board as a Non-Executive Director.
Andy Clark, Chairman of Immodulon Therapeutics, commented:
“We are very pleased to welcome Dr. Kampinga as Chief Executive of the Company. Jaap is highly capable as both a CEO and immunologist with a clear understanding of the commercial aspects of new product development. His experience in leading growing companies will be invaluable and he is well respected in the life science sector. We would like to share our deep gratitude to Kevin for leading us over the past two years, and we are delighted he will remain with the Company as a Non-Executive Director. As we move forward with our experienced management team and Scientific Advisory Board I am confident that we can realise Immodulon’s potential as a leading company in cancer immunotherapy.”
On his appointment, Dr Jaap Kampinga added:
“I am delighted to take on this role at Immodulon at an exciting time for the Company. We have a strong and experienced team here who I have worked closely with since joining as Chief Scientific Officer earlier this year. I believe Immodulon has a significant part to play in tackling some of the deadliest illnesses in the world and I look forward to driving the clinical progression of our lead immunotherapy compound, IMM-101.”